Today: 18 January 2026
Subscribe
Browse Category

Healthcare News News 9 December 2025 - 17 January 2026

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

New York, Jan 17, 2026, 08:04 ET — Market closed. ImmunityBio shares jumped on Friday and look set to remain in the spotlight when U.S. markets open again. The company revealed a steep rise in preliminary sales for its bladder cancer immunotherapy ANKTIVA, alongside a quicker-than-anticipated pace in trial enrollments. (Nasdaq) Why this matters now: these updates offer traders new…
17 January 2026
····
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

New York, Jan 12, 2026, 14:55 EST — Regular session Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab. (Smmttx) Summit’s filing marks its first attempt to introduce ivonescimab to…
12 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

NEW YORK, Jan 9, 2026, 07:03 EST — Premarket Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900…
9 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

New York, Jan 7, 2026, 15:40 (EST) — Regular session Merck & Co (MRK.N) shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics (CDTX.O) and expected to finish the acquisition through a merger later in the day. The company said the deal will…
7 January 2026
···
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

NEW YORK, December 31, 2025, 17:16 ET — After-hours Eli Lilly and Co (LLY) shares slipped in after-hours trading on Wednesday. The stock was down about 0.5% at $1,074.68, after trading between $1,074.39 and $1,083.25 during the day on roughly 1.5 million shares. Drug pricing has moved back to the center of the investment case for large-cap pharmaceuticals as Washington…
31 December 2025
···
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

NEW YORK, December 31, 2025, 04:27 ET — Premarket Vanda Pharmaceuticals’ shares surged about 18% in premarket trading on Wednesday after the U.S. Food and Drug Administration approved its motion-sickness vomiting drug, Nereus (tradipitant). StockAnalysis The approval matters now because Vanda is moving from a long-running regulatory story to a commercial one, with investors shifting quickly to questions of launch…
31 December 2025
···
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around…
23 December 2025
····
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

December 20, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending the year in classic Moderna fashion: a tug-of-war between near-term uncertainty (COVID policy and demand) and long-term optionality (a pipeline that still wants to be the sequel to the pandemic-era blockbuster). The stock last traded around $33.80, up roughly 9% from the prior close, with a market cap near $13…
20 December 2025
····
GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) announced today that the FDA approved Exdensur (depemokimab‑ulaa) for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc (LSE/NYSE: GSK) is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur (depemokimab‑ulaa)—a new twice‑yearly biologic for severe asthma—while…
17 December 2025
··
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and Company (NYSE: LLY)Stock price (last close):$1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but still powerful: blockbuster momentum in obesity/diabetes, fresh late-stage data that raises the bar for next-generation weight loss drugs, and a…
13 December 2025
···
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease. Immunovant, Inc. By late afternoon, Immunovant stock was trading around $25.75,…
11 December 2025
····
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes. GlobeNewswire This is the kind of setup that gets both momentum traders…
9 December 2025
····
1 2

Stock Market Today

  • NNN REIT trades at discount to DCF-based value; price US$42.64 vs intrinsic US$77.61
    January 18, 2026, 12:18 PM EST. NNN REIT trades at US$42.64, with 7-day, 30-day and YTD gains of 3.9%, 7.2% and 7.9%. Over 1 year it's up 12.8% and 5 years 37.6%. Simply Wall St assigns a valuation score of 5/6, citing the stock as undervalued on most checks. A two-stage DCF framework uses trailing free cash flow of about $616.6 million and projects $977.6 million in 2035, yielding an intrinsic value of US$77.61 per share and a 45.1% discount to the current price. The takeaway is that the stock looks undervalued on this model, though investors weigh the stability of a REIT against growth prospects; outcomes depend on cash-flow assumptions.
Go toTop